Clinical trial
Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients…
NCT00464880 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00464880 |
|---|---|
| Title | Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy |
| Official title | A Randomized, Double-Blind, Parallel-Group, Cross-Over, 4-Period, 4 Treatment, Within-Subject Placebo-Controlled Study to Assess the Reno-Protective Effect of Renin Inhibition With Aliskiren as an Alternative to Irbesartan in Type 2 Patients With Incipient/Overt Diabetic Nephropathy |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Type 2 |
| Intervention type | Drug |
| Interventions | Aliskiren |
| Enrollment | 24 |
| Start date | Sep 1, 2005 |
| Completion | Nov 1, 2007 |
| First posted | Apr 24, 2007 |
| Last update posted | Nov 29, 2007 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: